$SMTI
Sanara MedTech Inc. Stock $smti

$smti Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000165495421012077 Filed on November 12, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2021 Q2
Revenue	$7.033M	$5.824M	$6.277M
YoY Change	46.84%	35.24%	111.55%
Cost Of Revenue	$782.8K	$517.6K	$536.4K
YoY Change	59.75%	15.55%	53.84%
Gross Profit	$6.251M	$5.306M	$5.741M
YoY Change	45.36%	37.53%	119.24%
Gross Profit Margin	88.87%	91.11%	91.45%
Selling, General & Admin	$9.161M	$6.920M	$6.562M
YoY Change	80.69%	36.22%	81.27%
% of Gross Profit	146.56%	130.41%	114.31%
Research & Development	$300.8K	$35.67K	$104.0K
YoY Change		223.66%	150.46%
% of Gross Profit	4.81%	0.67%	1.81%
Depreciation & Amortization	$201.0K	$204.6K	$101.4K
YoY Change	151.26%	155.71%	26.75%
% of Gross Profit	3.22%	3.86%	1.77%
Operating Expenses	$9.663M	$7.160M	$6.767M
YoY Change	87.27%	38.62%	82.98%
Operating Profit	-$3.412M	-$1.854M	-$1.026M
YoY Change	296.79%	41.86%	-4.96%
Interest Expense	-$144.2K	$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$193.8K	$0.00
YoY Change		-296.21%	-100.0%
Pretax Income	-$3.557M	-$2.048M	-$1.206M
YoY Change	1217.26%	69.24%	6.72%
Income Tax
% Of Pretax Income
Net Earnings	-$3.548M	-$2.048M	-$1.206M
YoY Change	1319.32%	69.51%	6.77%
Net Earnings / Revenue	-50.45%	-35.16%	-19.21%
Basic Earnings Per Share		-$0.27	-$0.16
Diluted Earnings Per Share	-$471.4K	-$268.7K	-$156.3K
COMMON SHARES
Basic Shares Outstanding	7.632M shares	7.627M shares	7.497M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q4	2021 Q3	2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.65M	$29.51M	$24.39M
YoY Change	3954.97%	1292.18%	636.83%
Cash & Equivalents	$18.65M	$22.37M	$24.39M
Short-Term Investments		$7.143M
Other Short-Term Assets	$917.3K	$1.021M	$497.1K
YoY Change	50.38%	92.62%	-4.4%
Inventory	$2.048M	$1.552M	$1.538M
Prepaid Expenses
Receivables	$2.861M	$171.4K	$2.495M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$24.61M	$27.23M	$28.92M
YoY Change	449.01%	415.71%	373.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.630M	$1.581M	$1.669M
YoY Change	140.18%	122.72%	122.53%
Goodwill
YoY Change
Intangibles	$4.728M	$4.836M	$3.785M
YoY Change	52.63%
Long-Term Investments	$5.017M	$3.812M	$4.005M
YoY Change	356.12%	662.31%
Other Assets
YoY Change
Total Long-Term Assets	$11.79M	$10.70M	$9.866M
YoY Change	120.59%	144.81%	147.88%
TOTAL ASSETS
Total Short-Term Assets	$24.61M	$27.23M	$28.92M
Total Long-Term Assets	$11.79M	$10.70M	$9.866M
Total Assets	$36.40M	$37.93M	$38.78M
YoY Change	270.4%	293.04%	284.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$438.2K	$321.4K	$313.6K
YoY Change	61.53%	-13.14%	-64.77%
Accrued Expenses	$5.428M	$3.705M	$3.375M
YoY Change	77.98%	41.95%	34.47%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.022M	$4.158M	$3.746M
YoY Change	70.13%	34.57%	4.35%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities		$90.29K	$90.29K
YoY Change		-82.96%	-81.94%
Total Long-Term Liabilities	$222.2K	$347.0K	$381.0K
YoY Change	-50.2%	-65.3%	-57.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.022M	$4.158M	$3.746M
Total Long-Term Liabilities	$222.2K	$347.0K	$381.0K
Total Liabilities	$6.244M	$4.505M	$4.127M
YoY Change	56.66%	18.56%	-2.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$15.24M	-$11.41M	-$9.385M
YoY Change	116.65%
Common Stock	$45.88M	$7.632K	$7.612K
YoY Change	728428.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$30.64M	$33.42M	$34.66M
YoY Change
Total Liabilities & Shareholders Equity	$36.40M	$37.93M	$38.78M
YoY Change	270.4%	293.04%	284.39%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021 Q2
OPERATING ACTIVITIES
Net Income	-$3.548M	-$2.048M	-$1.206M
YoY Change	1319.32%	69.51%	6.77%
Depreciation, Depletion And Amortization	$201.0K	$204.6K	$101.4K
YoY Change	151.26%	155.71%	26.75%
Cash From Operating Activities	-$1.784M	-$1.434M	-$335.9K
YoY Change	202.43%	102.01%	-52.01%
INVESTING ACTIVITIES
Capital Expenditures	-$141.7K	-$583.3K	-$25.45K
YoY Change	-70.48%		-95.76%
Acquisitions
YoY Change
Other Investing Activities	-$1.350M	$0.00	-$2.584M
YoY Change	125.0%	-100.0%
Cash From Investing Activities	-$1.492M	-$583.3K	-$2.610M
YoY Change	38.12%	16.66%	334.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-442.5K	0.000	-740.0
YoY Change	-4525.3%	-100.0%	-100.13%
NET CHANGE
Cash From Operating Activities	-1.784M	-1.434M	-335.9K
Cash From Investing Activities	-1.492M	-583.3K	-2.610M
Cash From Financing Activities	-442.5K	0.000	-740.0
Net Change In Cash	-3.719M	-2.018M	-2.946M
YoY Change	124.01%	70.98%	309.22%
FREE CASH FLOW
Cash From Operating Activities	-$1.784M	-$1.434M	-$335.9K
Capital Expenditures	-$141.7K	-$583.3K	-$25.45K
Free Cash Flow	-$1.643M	-$851.0K	-$310.5K
YoY Change	1393.32%	19.86%	210.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7632044	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22371434	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	455366	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	97397	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100189	USD
CY2021Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	2064080	USD
CY2020Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	2217533	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	171440	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	872662	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2021Q3	smti	Royalty Receivable RoyaltyReceivable	49344	USD
CY2020Q4	smti	Royalty Receivable RoyaltyReceivable	49344	USD
CY2021Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	184870	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	276603	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	1552350	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	1148253	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1020901	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	611817	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	27229549	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	4482313	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	252138	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	124691	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1581298	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	678589	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	469702	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	467653	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1095628	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	827108	USD
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4835854	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3097666	USD
CY2021Q3	us-gaap	Long Term Investments LongTermInvestments	3811531	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	1100000	USD
CY2021Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	10698385	USD
CY2020Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	5343908	USD
CY2021Q3	us-gaap	Assets Assets	37927934	USD
CY2020Q4	us-gaap	Assets Assets	9826221	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	321391	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	271251	USD
CY2021Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	132134	USD
CY2020Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	223589	USD
CY2021Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	598167	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	502191	USD
CY2021Q3	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	2880461	USD
CY2020Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	2417277	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	226138	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	125587	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4158291	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3539895	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	256718	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	355797	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	90293	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	90293	USD
CY2021Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	347011	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	446090	USD
CY2021Q3	us-gaap	Liabilities Liabilities	4505302	USD
CY2020Q4	us-gaap	Liabilities Liabilities	3985985	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7632044	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6297008	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	7632	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	6297	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	45300968	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	13176576	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11405848	USD
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	33902752	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7032242	USD
	us-gaap	Revenues Revenues	10797838	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6150631	USD
	us-gaap	Revenues Revenues	17110511	USD
CY2021Q3	us-gaap	Minority Interest MinorityInterest	-480120	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	-310395	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	33422632	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	5840236	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37927934	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9826221	USD
CY2021Q3	us-gaap	Revenues Revenues	5823942	USD
CY2020Q3	us-gaap	Revenues Revenues	4306324	USD
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	517611	USD
CY2020Q3	us-gaap	Cost Of Revenue CostOfRevenue	447935	USD
	us-gaap	Cost Of Revenue CostOfRevenue	1528449	USD
	us-gaap	Cost Of Revenue CostOfRevenue	1126798	USD
CY2021Q3	us-gaap	Gross Profit GrossProfit	5306331	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	3858389	USD
	us-gaap	Gross Profit GrossProfit	15582062	USD
	us-gaap	Gross Profit GrossProfit	9671040	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6920105	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5072402	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18891979	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13632967	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35674	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11022	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	257867	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11022	USD
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	204570	USD
CY2020Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	81880	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	395968	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	209606	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	7160349	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	5165304	USD
	us-gaap	Operating Expenses OperatingExpenses	19545814	USD
	us-gaap	Operating Expenses OperatingExpenses	13853595	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1854018	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1306915	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3963752	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4182555	USD
CY2021Q3	us-gaap	Other Income OtherIncome	0	USD
CY2020Q3	us-gaap	Other Income OtherIncome	100250	USD
	us-gaap	Other Income OtherIncome	0	USD
	us-gaap	Other Income OtherIncome	14776	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	0	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	1458	USD
	us-gaap	Interest Expense InterestExpense	711	USD
	us-gaap	Interest Expense InterestExpense	10913	USD
CY2021Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-193843	USD
CY2020Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-472747	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-193843	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	98792	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-473458	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3863	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	584244	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	228786	USD
	smti	Interest Expense On Convertible Debt InterestExpenseOnConvertibleDebt	8354	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1205973	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	34657463	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2047861	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	33422632	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4437210	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4178692	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	395968	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	209606	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2047861	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1208123	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-4437210	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-4178692	USD
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-27491	USD
CY2020Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-60897	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-63604	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-68745	USD
CY2021Q3	smti	Net Loss Attributable To Sanara Medtech Common Shareholders NetLossAttributableToSanaraMedtechCommonShareholders	-2020370	USD
CY2020Q3	smti	Net Loss Attributable To Sanara Medtech Common Shareholders NetLossAttributableToSanaraMedtechCommonShareholders	-1147226	USD
	smti	Net Loss Attributable To Sanara Medtech Common Shareholders NetLossAttributableToSanaraMedtechCommonShareholders	-4373606	USD
	smti	Net Loss Attributable To Sanara Medtech Common Shareholders NetLossAttributableToSanaraMedtechCommonShareholders	-4109947	USD
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.60
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.72
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7518165	shares
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6230648	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7279708	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5730554	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	6392400	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	0	USD
CY2020Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1611911	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	393740	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-1841012	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	6557039	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	186171	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-1129557	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	5613653	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	750000	USD
CY2020Q3	smti	Employee Stock Purchase Program Amount EmployeeStockPurchaseProgramAmount	26220	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	381594	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-1208123	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	5563344	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	5840236	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1750000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	28939257	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	325518	USD
CY2021Q1	smti	Distribution To Noncontrolling Interest DistributionToNoncontrollingInterest	-200000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-1183376	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	35471635	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	297922	USD
CY2021Q2	smti	Capital Contribution Of Noncontrolling Interest CapitalContributionOfNoncontrollingInterest	93879	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	2897	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	87503	USD
	smti	Common Stock Issued For Asset Acquisitions CommonStockIssuedForAssetAcquisitions	750000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	51536	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	118022	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	30000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	106823	USD
	us-gaap	Inventory Write Down InventoryWriteDown	258585	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	852226	USD
	smti	License Agreement As Capital Contribution From Noncontrolling Interest LicenseAgreementAsCapitalContributionFromNoncontrollingInterest	93879	USD
	us-gaap	Proceeds From Loan Originations1 ProceedsFromLoanOriginations1	0	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	455366	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6611928	USD
CY2021Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	22371434	USD
CY2020Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	2120243	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	711	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
	smti	Common Stock Issued For Conversion Of Series F Preferred Stock CommonStockIssuedForConversionOfSeriesFPreferredStock	11368150	USD
	smti	Common Stock Issued For Conversion Of Related Party Debt And Interest CommonStockIssuedForConversionOfRelatedPartyDebtAndInterest	1611911	USD
	smti	Common Stock Issued For Asset Acquisitions CommonStockIssuedForAssetAcquisitions	2334244	USD
	smti	Interest Expense On Convertible Debt InterestExpenseOnConvertibleDebt	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	101916	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-536263	USD
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-171441	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-510920	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-299888	USD
	smti	Increase Decrease In Prepaid Deferred Expense And Other Assets Related Parties IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsRelatedParties	-50970	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-409084	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-320195	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	50140	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-62934	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-91454	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	26139	USD
	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	95976	USD
	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	140898	USD
	smti	Increasedecreaseinaccrued Bonus And Commissions IncreasedecreaseinaccruedBonusAndCommissions	344587	USD
	smti	Increasedecreaseinaccrued Bonus And Commissions IncreasedecreaseinaccruedBonusAndCommissions	366290	USD
	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	2559	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3030168	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3443449	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	30157	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	57456	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	578586	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1100000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	3184278	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	500000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3793021	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1657456	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	800000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	800000	USD
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	0	USD
	us-gaap	Proceeds From Loan Originations1 ProceedsFromLoanOriginations1	583000	USD
	smti	Public Offering Net Proceeds PublicOfferingNetProceeds	-28939257	USD
	smti	Increase Decrease In Prepaid Deferred Expense And Other Assets Related Parties IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsRelatedParties	0	USD
	smti	Common Stock Issued For Employee Stock Purchase Plan CommonStockIssuedForEmployeeStockPurchasePlan	26220	USD
	smti	Distribution To Noncontrolling Interest Shareholders DistributionToNoncontrollingInterestShareholders	200000	USD
	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28739257	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	609220	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	21916068	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4491685	USD
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>NOTE 1 – NATURE OF BUSINESS AND BACKGROUND</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Sanara MedTech Inc. (“we”, “our”, the “Company”) is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical and chronic wound and skin care markets. The Company’s portfolio of products and services is designed to allow us to deliver comprehensive wound and skin care solutions for patients in all care settings, including acute (hospitals and long-term acute care hospitals) and post-acute (wound care clinics, physician offices, skilled nursing facilities (“SNFs”), home health, hospice, and retail). Each of the Company’s products, services, and technologies contributes to the Company’s overall goal of achieving better clinical outcomes at a lower overall cost for patients regardless of where they receive care. The Company strives to be one of the most innovative and comprehensive providers of effective wound and skin care products and technologies.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Impact of the COVID-19 Pandemic</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Beginning in March 2020, many states issued orders suspending elective surgeries in order to free-up hospital resources to treat COVID-19 patients. This resulted in a reduction in demand for the Company’s surgical products beginning in the second half of March 2020. Additionally, most states limited access to SNFs to only resident caregivers, which impeded the Company’s ability to provide education and product training to the clinicians who use the Company’s products in these facilities. These restrictions resulted in an overall decline in sales for the second quarter of 2020. During the second half of 2020 and the first half of 2021, the Company saw a strong rebound in product sales as restrictions on elective surgeries eased in its primary markets in Texas, Florida, and the southeastern United States. During the third quarter of 2021, the United States experienced a surge of COVID-19 cases as the Delta variant of the virus impacted much of the country and negatively impacted the Company’s sales in Texas, the northeastern United States, and other markets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The duration and effects of the pandemic remain uncertain; however, management believes that elective surgical procedures will continue to be performed with the exception of certain geographic hotspots. Additionally, management believes that the majority of surgical procedures impacted by COVID-19 and its variants will ultimately be performed. The Company continues to closely monitor the pandemic in order to ensure the safety of the Company’s people and its ability to serve its customers and patients.</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition, and results of operations is highly uncertain and subject to change. The Company considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and determined there was not a material impact on the Company’s estimates and assumptions used in preparing the unaudited consolidated financial statements as of and for the nine months ended September 30, 2021. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p>
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	30000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	64899	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	64989	USD
CY2021Q3	smti	Other Allowances OtherAllowances	32498	USD
CY2020Q4	smti	Other Allowances OtherAllowances	35200	USD
	us-gaap	Revenues Revenues	17110511	USD
	us-gaap	Revenues Revenues	10797838	USD
	us-gaap	Sale Of Stock Percentage Of Ownership After Transaction SaleOfStockPercentageOfOwnershipAfterTransaction	0.020	pure
CY2021Q3	us-gaap	Sale Leaseback Transaction Quarterly Rental Payments SaleLeasebackTransactionQuarterlyRentalPayments	50250	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	51536	USD
	us-gaap	Inventory Write Down InventoryWriteDown	106823	USD
	us-gaap	Inventory Write Down InventoryWriteDown	258585	USD
CY2021Q3	smti	Allowance For Obsolete And Slow Moving Inventory AllowanceForObsoleteAndSlowMovingInventory	184870	USD
CY2020Q4	smti	Allowance For Obsolete And Slow Moving Inventory AllowanceForObsoleteAndSlowMovingInventory	276603	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1833436	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	803280	USD
CY2021Q3	smti	Less Accumulated Depreciation LessAccumulatedDepreciation	252138	USD
CY2020Q4	smti	Less Accumulated Depreciation LessAccumulatedDepreciation	124691	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1581298	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	678589	USD
	us-gaap	Depreciation Depreciation	127448	USD
	us-gaap	Depreciation Depreciation	50593	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3924774	USD
CY2020Q4	smti	Accumulated Amortization AccumulatedAmortization	-827108	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3097666	USD
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P12Y3M18D
CY2021Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5931482	USD
CY2021Q3	smti	Accumulated Amortization AccumulatedAmortization	1095628	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4835854	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	268520	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	159013	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	112163	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	446236	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	441156	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	441156	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	441156	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2953987	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4835854	USD
	smti	Royalties Payable Minimum RoyaltiesPayableMinimum	400000	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	756951	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	337639	USD
	us-gaap	Royalty Expense RoyaltyExpense	82500	USD
	us-gaap	Royalty Expense RoyaltyExpense	75000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	469702	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	482856	USD
	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	118022	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	139667	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	14.26
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11500	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	18.12
	smti	Forfeited Forfeited	-4786	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	13.03
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	111590	shares
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	63889	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	221793	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	154271	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	77870	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	517823	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	34967	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	482856	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	226138	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	256718	USD
	smti	Operating Leases Weighted Average Remaining Lease Term1 OperatingLeasesWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0583	pure
CY2021Q1	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	1500000	USD
CY2021Q1	us-gaap	Preferred Stock Dividends Shares PreferredStockDividendsShares	1136815	shares
CY2021Q1	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	2452731	shares
CY2021Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	3519019	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7632044	shares
CY2021Q1	us-gaap	Capital Leases Future Minimum Payments Next Rolling Twelve Months CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths	750000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	10083	shares
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	394073	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	852226	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	872662	USD
CY2021Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	950313	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y8M12D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	170178	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	14.20
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	10083	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	39.08
	smti	Vested Vested	-63885	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	11500	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.00
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11500	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.00
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y3M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P1Y3M18D
CY2021Q3	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	1000000	USD
CY2019Q2	smti	Revolving Line Of Credit Increase In Principal Amount RevolvingLineOfCreditIncreaseInPrincipalAmount	2500000	USD
CY2019Q4	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	2200000	USD
CY2021Q1	us-gaap	Line Of Credit LineOfCredit	800000	USD
CY2021Q3	us-gaap	Long Term Investments LongTermInvestments	500000	USD
CY2021Q3	us-gaap	Marketable Securities MarketableSecurities	7142857	USD
CY2021Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-193843	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-472747	USD
CY2020Q4	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	0	USD
CY2021Q3	us-gaap	Cost Method Investments Fair Value Disclosure CostMethodInvestmentsFairValueDisclosure	2584278	USD
CY2020Q4	us-gaap	Cost Method Investments Fair Value Disclosure CostMethodInvestmentsFairValueDisclosure	1100000	USD
CY2021Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	3811531	USD
CY2020Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	1100000	USD
CY2021Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-193843	USD
CY2020Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-472747	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
	smti	Total Purchase Price Table Textblock TotalPurchasePriceTableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Description</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net cash consideration</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">496,100</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity consideration (fair value)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">584,244</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net liabilities assumed</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,900</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Transaction costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">78,586</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"><strong>Total purchase consideration</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>1,162,830</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2021Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	496100	USD
CY2021Q3	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	584244	USD
CY2021Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3900	USD
CY2021Q3	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	78586	USD
CY2021Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	1162830	USD
CY2021Q3	us-gaap	Professional Fees ProfessionalFees	177697	USD
CY2021Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	1162830	USD
CY2021Q3	smti	Percent Of Total PercentOfTotal	1.000	pure
CY2021Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	132134	USD
CY2020Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	223589	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	171440	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
	smti	Technology Services Cost TechnologyServicesCost	234153	USD
CY2021Q3	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	95203	shares

Files In Submission

Name	View Source	Status
0001654954-21-012077-index-headers.html	Edgar Link	pending
0001654954-21-012077-index.html	Edgar Link	pending
0001654954-21-012077.txt	Edgar Link	pending
0001654954-21-012077-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
smti-20210930.xsd	Edgar Link	pending
smti-20210930_cal.xml	Edgar Link	unprocessable
smti-20210930_def.xml	Edgar Link	unprocessable
smti-20210930_lab.xml	Edgar Link	unprocessable
smti-20210930_pre.xml	Edgar Link	unprocessable
smti_10q.htm	Edgar Link	pending
smti_10q_htm.xml	Edgar Link	completed
smti_ex311.htm	Edgar Link	pending
smti_ex312.htm	Edgar Link	pending
smti_ex321.htm	Edgar Link	pending
smti_ex322.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SMTI
Sanara MedTech Inc. Stock $smti

2021 Q4 Form 10-Q Financial Statement

#000165495421012077 Filed on November 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMTI Sanara MedTech Inc. Stock $smti

2021 Q4 Form 10-Q Financial Statement

#000165495421012077 Filed on November 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMTI
Sanara MedTech Inc. Stock $smti